Compare FRSX & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRSX | SNOA |
|---|---|---|
| Founded | N/A | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.0M |
| IPO Year | 2016 | 2006 |
| Metric | FRSX | SNOA |
|---|---|---|
| Price | $1.55 | $1.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 126.9K |
| Earning Date | 05-15-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,288,000.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 12.19 |
| 52 Week Low | $0.31 | $0.85 |
| 52 Week High | $3.00 | $6.92 |
| Indicator | FRSX | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 38.55 |
| Support Level | $0.83 | $1.00 |
| Resistance Level | $2.27 | $1.23 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 23.12 | 30.36 |
Foresight Autonomous Holdings Ltd is a technology company engaged in the development of 3D perception systems and cellular-based applications. The company designs, develops, and commercializes in-line-of-sight vision systems and beyond-line-of-sight accident prevention solutions through its subsidiaries. Its solutions are based on stereo vision, 3D perception, and V2X technologies, aimed at improving safety by enabling accurate obstacle detection and real-time alerts. The company targets multiple industries, including automotive, defense, agriculture, and heavy equipment.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.